JohnFrancisFoleyMD

Neurology • Salt Lake City, UT

Neuroimmunology/Multiple Sclerosis

Physician

Join to view full profile

Dr. Foley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Foley's full profile

Already have an account?

Office
370 9th Ave
Suite 106
Salt Lake City, UT 84103
Phone+1 801-408-5700

Fax+1 801-405-5704

Education & Training

University of Utah HealthResidency, Neurology, 1984 - 1987
University of Utah HealthInternship, Internal Medicine, 1983 - 1984
Medical College of WisconsinClass of 1983

Certifications & Licensure

UT State Medical License 1984 - 2026
CO State Medical License 1987 - 1989
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Clinical Trials

Pharmacokinetic, Immunological and Biochemical Sample Collection and Analysis of a Tysabri Patient Cohort Start of enrollment: 2010 Feb 01
Completed
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
Completed
Phase 2
Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical Start of enrollment: 2011 Apr 01
Completed
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis Start of enrollment: 2012 Nov 01
Completed
Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation Start of enrollment: 2014 Jul 01
Terminated
Phase 4
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
Terminated
Phase 3
Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS Start of enrollment: 2016 Oct 01
Completed
Join now to see all

Publications & Presentations

PubMed

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri) Dosing: NOVA Phase IIIb Extension Study (Part 2).
Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A Cohen
Neurology and Therapy. 2024-10-01
Intact natalizumab pharmacokinetics is impacted by endogenous IgG4 concentration.
Lesley J Page, Iona F Pay, Edward T Castellana, Raphaela Heussen, Tamara Hoyt
Multiple Sclerosis and Related Disorders. 2024-07-01
Palmitoylation promotes pores.
John F Foley
Science Signaling. 2024-06-25